Engineering Medicines To Improve Patient Care Patients Treatments Targeting Patients’ Needs “Viridian is developing creative solutions to ease patient burdens – from their disease but also the burdens patients often bear in receiving clinically efficacious interventions. We aspire to develop medications that improve patients’ lives safely, tolerably, and conveniently.” – Barrett Katz, MD, MBA, Chief Medical Officer About TED What is Thyroid Eye Disease? Thyroid Eye Disease (known as TED) is a rare autoimmune disease in which your body’s own immune system and its antibodies attack the tissues around your eyes, causing swelling and damage. What are the signs and symptoms of TED? Although the signs and symptoms of TED can be very different from one person to another, people with TED may experience: Irritation, dryness and discomfort of your eyes and eyelidsPain on and difficulty moving your eyesEyelid retractionBulging eyesDouble vision What are the risk factors for developing TED? Although we do not fully understand what causes TED, experts have identified several factors that put some people at a greater risk of experiencing this disease. These include: Age: While TED can occur at any age, it usually develops before the age of 40Gender: TED is seven times more common in women than menHistory: TED usually occurs when there is a history of Graves’ diseaseSmoking: TED is more common in those who smoke or are exposed to second-hand smoke VRDN-001 Clinical Trials Viridian is developing treatments for Thyroid Eye Disease (TED), a debilitating auto-immune disease. Randomized, placebo controlled clinical trials are the mechanism dictated by the Food and Drug Administration that allows us to evaluate innovative new treatments to demonstrate efficacy, safety and tolerability of our pipeline products. We have initiated our first clinical trial in TED, seeking to enroll patients diagnosed with TED in the last 12 months. Click here to see a list of current clinical trial sites.